<DOC>
	<DOCNO>NCT00243178</DOCNO>
	<brief_summary>The purpose study determine combination Clopidogrel 75mg daily ( od ) plus aspirin 100mg daily ( recommend dose ) effective oral anticoagulation therapy low risk bleed patient atrial fibrillation associate least one major cardiovascular risk factor.Primary objective : The combination clopidogrel plus aspirin compare adjust dose ( INR 2.0 3.3 ) oral anticoagulation ( vitamin K antagonist ) result risk composite outcome stroke , non-CNS systemic embolism , myocardial infarction vascular death patient atrial fibrillation.The secondary objective establish whether aspirin plus clopidogrel low risk hemorrhage standard anticoagulation therapy .</brief_summary>
	<brief_title>Atrial Fibrillation Clopidogrel Trial With Irbesartan Prevention Vascular Events ( ACTIVE W )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Evidence atrial fibrillation either one current Electrocardiogram ( ECG ) two ECG record two week part 6 month prior study enrollment . Evidence high risk vascular event : least one follow risk criterion must present : 75 year great ; treatment systemic hypertension ; prior stroke , TIA , nonCNS systemic embolus ; leave ventricular dysfunction leave ventricular ejection fraction ( EF ) estimate echocardiogram angiogram ( radionuclide contrast ) &lt; 45 % ; peripheral vascular disease ( previous peripheral artery revascularization , limb foot amputation , combination current intermittent claudication ankle arm systolic blood pressure ratio &lt; 0.9 ) ; age 55 74 year ; AND either diabetes mellitus require drug therapy , document previous myocardial infarction , document coronary artery disease . Patients exclude ACTIVE follow present : requirement clopidogrel ( recent coronary stent procedure ) ; requirement oral anticoagulant ( prosthetic mechanical heart valve ) ; prior intolerance ASA clopidogrel ; document peptic ulcer disease within previous 6 month ; prior intracerebral hemorrhage ; significant thrombocytopenia ; ( platelet count &lt; 50 x 10 ( 9 ) /L ) ; psychosocial reason make study participation impractical ; geographic reason make study participation impractical ; ongoing alcohol abuse ; mitral stenosis ; pregnant nursing woman woman child bear potential effective birth control least one month prior start study willing continue birth control duration study ; severe comorbid condition patient expect survive 6 month ; patient currently receive investigational pharmacologic agent ; OR requirement chronic ( &gt; 3 month ) nonCOX2 inhibitor NSAID therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Anticoagulant therapy</keyword>
	<keyword>Thromboembolic prevention</keyword>
</DOC>